Disclaimer: SAFE SA (the “Company”) has arranged financing in the form of convertible bonds into new or existing shares (OCEANE) with Global Corporate Finance Opportunities 20 (“GCFO 20”), which, after receiving the shares resulting from the conversion of these bonds, is not intended to remain a shareholder of the Company. The shares resulting from the conversion of these bonds will generally be sold on the market at very short notice, which may create strong downward pressure on the share price
FIRST-HALF 2024 SALES Fleurieux-sur-l’Arbresle - France - July 29, 2024, 6.00 p.m. The group Safe (FR001400F1V2 – ALSAF) announces consolidated sales for 1st half 2024. In k€First-half 2024*First-half 2023% changeSales 2 5872 909- 11,1%Safe Orthopaedics1 3031 726- 24,5%Safe Medical1 2841 183+ 8,5% * Unaudited 2024 figures The Safe Group's consolidated sales for the 1st half of 2024 came to €2.6 million, maintaining a good level. Over the period, the new management team implemented a large-scale
First implantations of the Sycamore device in Switzerland Fleurieux-sur-l’Arbresle - France – June 12, 2024 at 6 p.m. Safe SA, announces the first implantations of Sycamore devices by Professor Maestretti, at the cantonal hospital of Friborg in Switzerland. The Sycamore implant is a unique implant that allows minimally invasive operations to treat vertebral compression fractures, improve mobility, restore the height of vertebral bodies and reduce back pain (pedicle anchored kyphoplasty). This cu